Fintel reports that on August 7, 2023, Barclays maintained coverage of Twist Bioscience (NASDAQ:TWST) with a Overweight recommendation.
Analyst Price Forecast Suggests 0.93% Upside
As of August 2, 2023, the average one-year price target for Twist Bioscience is 23.97. The forecasts range from a low of 18.18 to a high of $34.65. The average price target represents an increase of 0.93% from its latest reported closing price of 23.75.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Twist Bioscience is 271MM, an increase of 15.08%. The projected annual non-GAAP EPS is -4.78.
What is the Fund Sentiment?
There are 458 funds or institutions reporting positions in Twist Bioscience. This is a decrease of 11 owner(s) or 2.35% in the last quarter. Average portfolio weight of all funds dedicated to TWST is 0.10%, a decrease of 48.75%. Total shares owned by institutions increased in the last three months by 3.93% to 77,783K shares. 
The put/call ratio of TWST is 1.15, indicating a bearish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 6,959K shares representing 12.18% ownership of the company. In it's prior filing, the firm reported owning 7,179K shares, representing a decrease of 3.16%. The firm increased its portfolio allocation in TWST by 26.70% over the last quarter.
Jpmorgan Chase holds 4,057K shares representing 7.10% ownership of the company. In it's prior filing, the firm reported owning 3,895K shares, representing an increase of 4.00%. The firm decreased its portfolio allocation in TWST by 39.04% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 3,997K shares representing 6.99% ownership of the company. In it's prior filing, the firm reported owning 3,190K shares, representing an increase of 20.20%. The firm decreased its portfolio allocation in TWST by 0.85% over the last quarter.
ARKK - ARK Innovation ETF holds 3,711K shares representing 6.49% ownership of the company. In it's prior filing, the firm reported owning 3,826K shares, representing a decrease of 3.11%. The firm decreased its portfolio allocation in TWST by 51.85% over the last quarter.
Sumitomo Mitsui Trust Holdings holds 3,566K shares representing 6.24% ownership of the company. In it's prior filing, the firm reported owning 3,402K shares, representing an increase of 4.61%. The firm increased its portfolio allocation in TWST by 47.66% over the last quarter.
Twist Bioscience Background Information
(This description is provided by the company.)
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Additional reading:
- Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results -- Record revenue of $63.7M in 3QFY23; Increase of 14% over $56.1M in Fiscal 2022 – -- Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M --
- Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
- Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – -- Decisive Actions to Accelerate Path to Profitab
- Amended and Restated Employment Agreement dated October 26, 2022 between Twist Bioscience Corporation and Patrick Finn.
- Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results – Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 –
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
